Catalent News

Goldman's Debt Issuers Stocks Basket

Seeking AlphaApr 23 00:53

323 drugs, hurry up! America is facing the biggest “drug shortage” in history...

The US now seems to be facing an unprecedented “drug shortage”...

cls.cnApr 15 14:37

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target Is $48

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48.

MT NewswiresApr 12 22:36

Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)

TipRanksApr 12 13:41

Top 10 Best Performing S&P 500 Health Care Stocks of 2024

Seeking AlphaApr 11 02:56

Novo Nordisk Parent Resubmits Application Seeking US Antirust Nod for Catalent Deal

Novo Nordisk (NOVO-B.CO) parent Novo Nordisk Foundation filed a new application to secure the US Federal Trade Commission's approval on its proposed acquisition of manufacturing subcontractor Catalent

MT NewswiresApr 9 12:05

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were easing late Monday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each down about 0.2% The iShares Biotechnology ETF (IBB) rose 0.

MT NewswiresApr 9 04:00

Sector Update: Health Care Stocks Flat to Higher Premarket Monday

Health care stocks were flat to higher premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. Alnylam Pharmaceuticals (ALNY) was

MT NewswiresApr 8 21:28

Novo Nordisk Parent Refiles US Application on Catalent Deal

Yahoo FinanceApr 8 18:31

Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal

BNN BloombergApr 6 04:55

Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

TipRanksApr 5 15:50

Beyond The Numbers: 6 Analysts Discuss Catalent Stock

In the preceding three months, 6 analysts have released ratings for Catalent (NYSE:CTLT), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates their recent

BenzingaApr 4 23:01

Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.

Catalent Price Target Maintained With a $63.50/Share by Stephens & Co.

Dow JonesApr 4 22:36

Stephens & Co. Reiterates Equal-Weight on Catalent, Maintains $63.5 Price Target

Stephens & Co. analyst Jacob Johnson reiterates Catalent with a Equal-Weight and maintains $63.5 price target.

Analyst UpgradesApr 4 22:26

Catalent Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 12.17% Stephens & Co. → $63.5 Reiterates Equal-Weight → Equal-Weight 02/20/2024 12.17% RBC Capi

BenzingaApr 4 22:24

Invenra Inc. Announces a Strategic Collaboration With Catalent to Co-Discover Novel Bispecific ADCs

Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in

BusinesswireApr 3 01:54

Aseptic Fill Finish Market Trends, Forecast and Competitive Analysis to 2030, Featuring AbbVie, Asymchem, Aenova, APL, BioPharma Solutions, BioReliance, Boehringer Ingelheim and Catalent Biologics

Yahoo FinanceApr 2 21:25

Eli Lilly Tops S&P 500 Healthcare Sector in Q1 as Weight Loss Frenzy Continues

Seeking AlphaMar 31 00:13

Softgel Capsules Market Size, Share & Trends Analysis Report 2023-2030, Featuring Fuji Capsule, Sirio Pharma, CAPTEK Softgel, Catalent, EuroCaps, Aenova, ProCaps Laboratories and Soft Gel Technologies

Yahoo FinanceMar 28 23:52

Catalent(CTLT.US) Officer Sells US$21,749.4 in Common Stocks

$Catalent(CTLT.US)$ Officer Gunther Scott sold 387 shares of Common Stocks on Mar 15, 2024 at an average price of $56.2 for a total value of $21,749.4.Source: Announcement What is statement of changes

Futu NewsMar 20 02:20